Last update :
08/05/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
Valistab
Valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Antimuscarinic   Scopolamine N-butyl bromide  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Buscapina Spain
Buscolysin Poland
Buscopan Australia, Austria, Belgium, Brazil, Canada, Egypt, Finland, Germany, Iceland, Luxembourg, Netherlands, New Zealand, Norway, Portugal, Sweden, Switzerland, Tunisia, Turkey, United Arab Emirates
Butilbromuro de hioscina Argentina, Colombia
Cifespasmo Argentina
Colobolina Argentina
Dolopina Ecuador
Escopolamina N butyl bromuro Chile
Hiocin Venezuela
Hioscina Argentina, Colombia, Peru
Hioscina butil bromuro Colombia, Peru
Hyocidic Iran
Hyoscine Australia
Hyoscine hydrobromide Canada
Hyotex Iran
Pasmodina Drawer Argentina
Rupe N Argentina
Scoburen France
Selpirans Venezuela
Spasmopan Tunisia
Xemol Turkey
Stability of mixtures   Injection   Stability of mixtures : Scopolamine N-butyl bromide     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Polypropylene Sodium chloride 0,9% 5 & 6,67 mg/ml
Injection   Scopolamine N-butyl bromide   
Injection   Haloperidol lactate 0,42 & 0,62 mg/ml
Injection   Morphine hydrochloride 1,67>> 10 mg/ml
25°C
15 Day
Protect from light 2055
Level of evidence B+
Polypropylene Sodium chloride 0,9% 3,33>>6,67 mg/ml
Injection   Scopolamine N-butyl bromide   
Injection   Tramadol hydrochloride 8,33>>33,3 mg/ml
25°C
15 Day
Protect from light 2176
Level of evidence B
Polypropylene Sodium chloride 0,9% 3,33>>6,67 mg/ml
Injection   Scopolamine N-butyl bromide   
Injection   Morphine hydrochloride 1,67>> 10 mg/ml
25°C
15 Day
Protect from light 1966
Level of evidence C+
Polypropylene Sodium chloride 0,9% 2,5 & 5 & 10 mg/ml
Injection   Scopolamine N-butyl bromide   
Injection   Haloperidol lactate 0,312 mg/ml
4°C
15 Day
Protect from light 1970
Polypropylene Sodium chloride 0,9% 3,33>>6,67 mg/ml
Injection   Scopolamine N-butyl bromide   
Injection   Tramadol hydrochloride 8,33>>33,3 mg/ml
4°C
15 Day
Protect from light 2176
Level of evidence B
Polypropylene Sodium chloride 0,9% 3,33>>6,67 mg/ml
Injection   Scopolamine N-butyl bromide   
Injection   Morphine hydrochloride 1,67>> 10 mg/ml
4°C
15 Day
Protect from light 1966
Level of evidence C+
Polypropylen Syringe Water for Injection 0,85 mg/ml
Injection   Scopolamine N-butyl bromide   
Injection   Fentanyl citrate 40 µg/ml
Injection   Midazolam hydrochloride 0,6 mg/ml
32°C
10 Day
Protect from light 1405
Level of evidence B
Not specified Sodium chloride 0,9% 3,33 >> 6,67 mg/ml
Injection   Scopolamine N-butyl bromide   
Injection   Tramadol hydrochloride 8,8 >> 33,3 mg/ml
Injection   Haloperidol lactate 0,208 >> 0,624 mg/ml
25°C
15 Day
Protect from light 3132
Level of evidence C+
  Mentions Légales